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Abstract
Background: Positron emission tomography (PET) with fluor-18-deoxy-glucose (FDG) is widely used for diagnosing
recurrent or metastatic disease in patients with differentiated thyroid cancer (DTC).
Purpose: To assess the diagnostic accuracy of FDG-PET for DTC in patients after ablative therapy.
Material and Methods: A systematic search was conducted in Medline/PubMed, EMBASE, Cochrane Library, Web of
Science, and Open Grey looking for all English-language original articles on the performance of FDG-PET in series of at
least 20 patients with DTC having undergone ablative therapy including total thyroidectomy. Diagnostic performance
measures were pooled using Reitsma’s bivariate model.
Results: Thirty-four publications between 1996 and 2014 met the inclusion criteria. Pooled sensitivity and specificity
were 79.4% (95% confidence interval [CI], 73.9–84.1) and 79.4% (95% CI, 71.2–85.4), respectively, with an area under the
curve of 0.858.
Conclusion: F18-FDG-PET is a useful method for detecting recurrent DTC in patients having undergone ablative
therapy.
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Introduction
Diﬀerentiated thyroid cancer (DTC) is the most
common malignant endocrine tumor. Although prog-
nosis is generally favorable, with reported 5-year sur-
vival rates of 95% for women and 87% for men (1),
some patients continue to experience adverse outcomes
despite improvements in imaging and surgical tech-
nique (2,3).
Serum human thyroglobulin (hTg) is a reliable
marker for persistent or recurrent disease after previous
ablative therapy with total thyroidectomy with or with-
out additional ablative radioiodine therapy (RIT).
Routine ultrasound of the neck is often negative in
these patients, as we recently demonstrated in a pro-
spective cohort from our institution (2). Scanning with
radioactive iodine, in particular after a therapeutic
activity of iodine 131 (I-131), may reveal tumor lesions
missed by conventional imaging (4). In two seminal
papers in 1995 and 1996, Feine et al. demonstrated
that positron emission tomography (PET) with ﬂuor-
18-deoxy-glucose (FDG) can detect tumor lesions that
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are missed by I-131-scintigraphy (5, 6). To explain their
ﬁndings, they postulated a ‘‘ﬂip-ﬂop-phenomenon’’,
whereby highly diﬀerentiated thyroid cancer cells
show iodine uptake due to the expression of sodium-
iodide symporter (NIS) but no glucose uptake, while
less diﬀerentiated cells that ceased to express NIS exhi-
bit upregulated glucose and FDG uptake (7–9).
Since then F18-FDG-PET has become an important
method in patients with DTC with suspected recurrent
or persistent DTC, as is evidenced in many series pub-
lished since the late 1990s. A systematic meta-analysis,
published by Dong et al. in 2009, documented a pooled
patient-based sensitivity of F18-FDG-PET of 83.5%
and speciﬁcity of 84.3% (10). We recently published
results from multimodal imaging including F18-FDG-
PET from a prospective cohort of 51 patients (2) and
wanted to compare our results with more current data
from the literature.
Material and Methods
We performed a systematic literature search for all
English-language original articles addressing diagnostic
performance of F18-FDG-PET in series of 20 patients
or more with suspected or known recurrence after pre-
vious ablative therapy published from 1996 until
31 December 2014.
More speciﬁcally, our selection criteria were: (i) all
patients had undergone previous ablative therapy
including total thyroidectomy; (ii) patients were sus-
pected of having recurrences and/or metastases or had
risk factors such as a measurable or rising hTg or cir-
culating hTg antibodies; (iii) patients underwent an
FDG-PET or combined hybrid FDG-PET/computed
tomography (CT) of the torso; (iv) reported study
data were suﬃcient to calculate sensitivity and speciﬁ-
city for tumor detection; (v) histology, cytology, or
follow-up were used as gold standard. Exclusion cri-
teria were: article types other than original articles
such as abstracts, letters, editorials, and comments.
When data or subsets of data were presented in more
than one article, the most recent article was chosen.
A systematic literature search was conducted on
17 February 2015 in ﬁve databases including Ovid
MEDLINE(R)/PubMed (http://www.ncbi.nlm.nih.
gov/pubmed; U.S. National Library of Medicine,
Bethesda/MD), EMBASE (Ovid), Cochrane Library
(Wiley), Web of Science (Thomson Reuters), and
Open Grey (http://www.opengrey.eu) using standar-
dized subject headings (MeSH, EMTREE) for thyroid
cancer and FDG or PET as well as their free-text
equivalents.. The detailed search strategy can be
obtained from the author.
All of 3625 hits were screened based on abstract and
title by two authors (MB, TH), and then further
analyzed based on the full manuscript. All relevant
manuscripts were available in full text format. To
assess the methodologic quality and the applicability
of the included articles, the QUADAS-2 instrument
was independently applied by the two authors (11).
As suggested by the QUADAS-2 instrument, additional
signaling questions were deﬁned. Based on the follow-
up results from our own cohort (2) we introduced an
extra signaling question ‘‘Is the mean or median follow-
up duration after imaging two years or more?’’ and we
assumed a risk of bias regarding the time/ﬂow domain
when it was not (see Supplementary Materials 1 [online
only] for further details on the study-speciﬁc signaling
questions and scoring criteria).
All pertinent data from the included articles were
registered in MDCake, a dedicated client-server data-
base application developed by our group for data
collection and management (12). The observers were
blinded to each other when entering QUADAS-
scores. Data were re-aggregated into a single SQL
view for qualitative as for statistical analysis. Pooled
diagnostic performance was estimated using R package
mada based on Reitsma’s bivariate model (13,14). The
application of univariate models for pooling sensitiv-
ities and speciﬁcities in diagnostic studies is no longer
considered appropriate (15).
Results
The literature search identiﬁed 34 studies with a total of
2639 patients meeting the inclusion criteria (6,16–48).
Eleven studies reported on the diagnostic accuracy of
single-modality PET, 17 on PET/CT, and six on both
PET and PET/CT (‘‘mixed’’). The pertinent details of
the 34 studies are presented in Supplementary Materials
2, Table (online only).
Methodological quality. QUADAS-2 scores are sum-
marized in Fig. 1. According to the QUADAS-2 stand-
ard, patient selection should be consecutive in a
prospective study design (11). The precise mode of
patient selection was however unclear in 14 (41%) of
the studies and apparently biased in three (9%). The
index test should be applied blinded to the outcomes or
in a prospective manner. This was insuﬃciently docu-
mented in nine (26%) of the studies. Most frequently
the reviewers had concerns regarding the timing and the
ﬂow of the studies: only in eight (24%) of the studies
was the duration of post-imaging follow-up considered
suﬃcient, while potential bias was found in 18 (53%) of
the studies and high risk of bias in eight (24%).
Meta-analysis. Forest plots of sensitivity and speciﬁ-
cities in the component studies are presented in Figs. 2
and 3. Pooled sensitivity and speciﬁcity of all studies in
relation to the reference standard were 79.4 % (95%
conﬁdence interval [CI], 73.9–84.1) and 79.4% (95%
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Fig. 2. Forest plot of the diagnostic sensitivities of the 34 component studies with 95% confidence intervals (continuity corrected).
Risk of bias Concerns regarding applicability
Patient selection
Index test
Reference standard
Flow/Timing
0% 25% 50% 75% 100% 0% 25% 50% 75% 100%
Studies
QU
AD
AS
2 
Do
m
ai
n
unclear
high
low
Fig. 1. Results of QUADAS-2 scoring of the 34 component studies according to the four QUADAS-2 domains patient selection,
index test, reference standard, and flow/timing (11).
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CI, 71.2–85.4), respectively, with an area under the
curve of 0.858 (Fig. 4). In a subgroup analysis, PET-
CT performed slightly better than single modality PET
(Table 1), but the diﬀerence was not statistically
signiﬁcant.
Discussion
F18-FDG-PET is a useful tool for evaluating patients
with suspected recurrence of DTC with a pooled sensi-
tivity of 79.4% and speciﬁcity of 79.4% across all stu-
dies. These results compare well to the most recent
systematic meta-analysis published in 2009, which
reported a pooled patient-based sensitivity and speciﬁ-
city of 81% (74–86%) and 82% (73–88%) based on 17
studies using comparable statistical methodology (10).
The stable, rather than improved diagnostic per-
formance over the past 5–6 years was surprising,
given the latest developments in imaging technology
such as high resolution PET-CT (Table 1). Although
PET-CT performs better than single-modality PET in
head-to-head comparisons (2,38), the eﬀect did not
reach statistical signiﬁcance in the meta-analysis.
Interestingly, pooled speciﬁcity was highest for
‘‘mixed’’ studies reporting on cohorts examined
with either single-modality PET or PET-CT. We
regard this as an outlier as the ‘‘mixed’’ studies
did not diﬀer in their QUADAS-2 scores from the
PET-CT studies.
The apparently constant diagnostic performance of
PET despite major advances in imaging technology can
hardly be explained by the considerable heterogeneity
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Fig. 3. Forest plot of the diagnostic specificities of the 34 component studies with 95% confidence intervals (continuity corrected).
The raw specificity in the study by Mirallie´ et al. was 0% (seven false positive FDG-PET studies among the seven patients without
detectable disease) (37).
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of the individual studies uderlying the present meta-
analysis, by publication bias or overoptimistic report-
ing (49,50). We suspect that this rather points to two
methodical ﬂaws common to most studies on our meta-
analysis. The generally accepted deﬁnition of a ‘‘true
positive’’ examination is the ﬁnding of at least one
true positive lesion in the imaging study conﬁrmed in
a surgical specimen or a biopsy regardless of the
False Positive Rate
Asa 2014
Özdemir  2014
Giovanella 2013
Bannas 2012
Kunawudhi 2012
Na 2012
Prestwich 2012
Rosenbaum−Krumme 2012
Kingpetch 2011
Lal 2010
Piciu 2010
Razfar 2010
Vera 2010
Freudenberg 2007
Palmedo 2006
Riemann 2013
van Dijk 2013
Vural 2012
Oh 2011
Seo 2010
Zuijdwijk 2008
Esteva 2009
Hung 2003
Helal 2001
Chung 1999
Grünwald 1999
Wang 1999
Dietlein 1997
Feine 1996
PET−CT
PET
mixed
100 90 80 70 60 50
50
60
70
80
90
10
0
Specificity (%)
Se
ns
itiv
ity
 (%
)
Fig. 4. Summary receiver operating characteristics (SROC) curve of the 34 component studies. Pooled sensitivity/specificity over all
studies is marked in the center of the plot with a surrounding 95% confidence ellipse. Sensitivity and specificity of the individual studies
are plotted in ROC space. PET, studies using single-modality PET; PET-CT hybrid PET + CT; mixed, studies reporting on a mixture of
PET and PET-CT; PET, studies using single-modality PET; PET-CT, hybrid PET þ CT.
Table 1. Pooled diagnostic performance of PET and PET/CT.
Type Studies (n) Patients (n) Pooled sensitivity Pooled specificity AUC
PET 11 640 76.6% (62.8–86.4) 75.7% (59.5–86.8) 0.826
PET-CT 17 905 80.2% (73.5–85.6) 75.5% (62.8–85.0) 0.844
Mixed 6 1094 82.1% (69.4–90.2) 91.2% (82.8–95.7) 0.933
All 34 2639 79.4% (73.9–84.1) 79.4% (71.2–85.4) 0.858
Pooled diagnostic performance measures with 95% confidence intervals.
AUC, area under the summary receiver operating characteristics (SROC) curve; PET, studies using single-modality PETonly; PET-CT hybrid PET + CT
only; mixed, mixture of PET and PET-CT in the same study; PET-CT, hybrid PETþCT.
An AUC of 1 represents an ideal test while a non-discriminatory test will have an AUC of 0.5.
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number of possible false negative lesions that may have
been overlooked. True positive and false negative
lesions can, however, coexist in the same patient, and
if overlooked in a thyroid cancer patient, may lead to
avoidable repeat surgery (2). Similarly, false positive
lesions, which may lead to unnecessary surgery, will
not be scored in patients who have at least one true
positive lesion. Thus patient-based sensitivity and
speciﬁcity tend to be overoptimistic compared with
lesion-based analysis. The second problem lies in the
composite reference standard that is based on a com-
bination of pathology, imaging, and clinical outcomes.
As discussed in our recent publication, prophylactic
surgery for DTC in the absence of imaging ﬁndings is
considered unethical (2). Thus the only means of iden-
tifying false negative (overlooked) ﬁndings in an ima-
ging study is careful patient follow-up. To a large
extent, this follow-up relies on the same imaging tech-
niques (e. g. ultrasound and PET) in which the false
negative lesion was potentially overlooked. Thus the
reference standard is not independent from the index
test. An independent reference standard is, however,
the fundamental assumption underlying diagnostic
accuracy studies (11). A similar issue occurs if image-
guided biopsy forms part of the composite standard:
Only lesions that are seen can be biopsied, thus a
biopsy will not guard against overlooked lesions.
Thyroid cancer is, as a rule, a slow growing tumor.
In our QUADAS-2 analysis, we therefore stipulated
that the mean or median follow-up should be 2 years
or more. This was based on our experience that, until
now, four overlooked false negative lesions in our series
were detected 0.9, 1.1, 1.1, and 3.8 years after the initial
PET study (2). We therefore suggest that future
diagnostic imaging studies in solid tumors employ
both patient-based and lesion-based analysis, and
follow-up of suﬃcient duration for the cancer type
under study.
Our meta-analysis has the following limitations.
First, we restricted our analysis to English language
articles. Second, we excluded studies with fewer than
20 subjects. Meaningful estimates of sensitivity and spe-
ciﬁcity need a minimum number of cases with and with-
out disease (51). However, the choice of the threshold
was arbitrary given that disease prevalence varies
between studies. Third, we abstained from conducting
extensive subgroup analyses, such as on the role of TSH
stimulation on the diagnostic performance of FDG-
PET, the presence or absence of iodine uptake, or the
correlation of serum hTg or hTg antibodies and true
positive PET ﬁndings. Given the considerable hetero-
geneity between the component studies, we do not
think a meta-analysis will provide reliable valid conclu-
sions. Finally, we did not pool lesion-based sensitivities
and speciﬁcities as there are were only ﬁve studies that
presented lesion-based diagnostic performance data
(Supplementary Table).
In conclusion, F18-FDG-PET continues to be a
useful method for detecting recurrent thyroid cancer,
with a pooled patient-based sensitivity of 79.4% and
speciﬁcity of 79.4% across all studies.
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